Crowdonomics
All companies
Stride Tech Medical logo

Stride Tech Medical

Operating

StrideTech Medical, Inc.

Healthcare · Technology · Boulder, CO · Founded 2019

Smart walkers prevent falls with an innovative walker attachment technology

Post-money valuation
$80.4M
As of Nov 2022 · from Stride Tech Medical Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$207,395
Across 1 round since 2022
Latest share price
$1.39
Stride Tech Medical Common Stock 1 offering price

Financials

FY2019–FY2022 · from SEC filings · hover any figure for its source
$0
−$147K
2019
$0
−$147K
2020
$0
−$216K
2021
$66
−$245K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019
FY2020
FY2021
FY2022
Income statement
Revenue
$0
$0
$0
$66
Cost of goods sold
$0
$0
$175
$175
Gross margin
-165%
Net income
-$147,115
-$147,115
-$216,408
-$245,146
Taxes paid
$0
$0
$0
$0
Balance sheet
Cash
$79,416
$79,416
$39,938
$35,872
Accounts receivable
$0
$0
$0
$0
Total assets
$90,106
$90,106
$51,018
$44,774
Short-term debt
$4,004
$4,004
$0
$0
Long-term debt
$180,500
$180,500
$330,000
$354,990
Total liabilities
$184,504
$184,504
$330,000
$354,990
Other
Headcount
6
6
5

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Post-money = pre-money + amount raised · caps marked
$80.4M
post-money
Stride Tech Medical Common Stock 1

A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.

Fundraising history

Stride Tech Medical Common Stock 1ClosedReg CF · Common Equity · via StartEngine
Raised $207.4K / $1MInvestors 94Post-money $80.4M

Team

11 people
Andrew PlumFounder
Director, Chief Technology Officer

Andrew has a background in mechanical engineering with skills in hardware and embedded system design. Andrew uses his expertise in mechanical design, IoT embedded systems, and electrical engineering to advance the technology behind Stride Tech.

George DouaireFounder
Director, President & CEO

George has been an Executive leader for organizations ranging from start-ups to $14 billion Fortune 50 corporations. He brings an exceptional management record of growth in profits, sales, market penetration & customer service. He has achieved or exceeded objectives through innovative deal creation, contract negotiations & creative team development, domestically and internationally. George has been a mentor at Boomtown Accelerator, Boulder and is currently an Instructor at the Leeds School of Business. He has been on the boards of several companies (publicly traded and privately owned) and served on the national board for the Platform Tennis Association and as a volunteer with the Community Health Initiative in Haiti (surgical support team).

Humsini AcharyaFounder
Director

Humsini has a background in neuromechanics and rehabilitation engineering research. There she saw many solutions for posture and gait problems with older adults that only tended to help in strict laboratory settings. Most solutions were unlikely to be implemented in the real world, let alone be commercially viable. Humsini now uses her research background to ensure that StrideTech Go is founded on research, efficacy, and testing.

Timothy Visos-ElyFounder
Director, Chief Product Officer

Tim gained experience in the medical device industry by designing walkers for Medline, one of the largest DME (Durable Medical Equipment) companies in the world. Through this experience he learned about the unaddressed issues with walker design for seniors. Given a personal motivation to help his Grandmother stop falling when using her walker, Tim proposed his design for an Engineering Project at CU - Boulder. It was in this class where Tim built out the team and product.

Carrie Coumbs
Advisor

Ms. Coumbs is an experienced growth strategist, in the senior housing, geriatric rehabilitation, Medicare ACO, CPC+ and BPCI-A. She is a passionate executive leader in home health, hospice care and home care collaboration. Ms. Coumbs brings StrideTech experience in Accountable Care Organization, and is a Medicare/Medicaid specialist.

Christopher Krause
Advisor

Mr. Krause is an engaging Occupational Therapist and rehabilitation operations leader with a demonstrated history of success in healthcare and senior care rehab technology innovation. Krasue’s clinical experience, communication, and team building skills will accelerate StrideTech’s product growth and new sales through creation of new engagement technologies and clinical concepts across a vast array of settings including acute care, sub-acute, home health, and assisted living

Jack York
Advisor

Mr. York, a co-founder of It’s Never 2 Late, also known as iN2L brings expert experience in integrated hardware, software and media systems. York’s expertise working with over 2,500 senior living communities – including independent living, assisted living, memory care, nursing homes and adult day programs – in all 50 states and three countries will be invaluable to StrideTech as the company continues to grow. York regularly speaks at conferences and conventions in the senior services industry.

Jacob Segil
Advisor

Jacob Segil is currently the Program Director at the Center for Translational Research at University of Colorado Boulder where he acts as a campus-wide resource for faculty and staff who are pursuing funding to seed early-stage companies based upon university inventions. Dr. Segil has also founded multiple startup companies in the medical device space including: Point Designs LLC, MITA, LLC, and Infinite Biomedical Technologies LLC.

Larry Blankenship
Advisor

Mr. Blankenship has served as Director, CEO, President, COO and CTO of multiple start-up companies and has served in executive positions for large healthcare and research firms. Mr. Blankenship currently provides personal advisory and consulting services to companies in the medical device and life science industries including business and product strategies at the Board and C-executive level.

Show 2 more people
Nathan Estrada
Advisor

Dr. Estrada spent the first decade of his career as a physical therapist working directly with older adults as the Senior Living Program Manager at Bayada where he had first-hand experience treating people who use walkers. Dr. Estrada has translated his experience and knowledge into creating technology to solve the industry's biggest problems and now works as Vice President of Clinical at Nymbl Science.

Param Singh
Advisor

Dr. Param Singh is one of two inventors of the AbioCor, the first total artificial heart (Patent 4,888,011). Mr. Singh is now retired from Abiomed after building the company from formation to an IPO. Dr. Singh has enjoyed being a mentor to entrepreneurs and investing his time in worthy start-ups in the medical field.

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFewer than 300 holders of record

Filed 2 of 5 annual reports (FY2021–FY2025)

94 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form C-ARJun 2, 20230001665160-23-001341
    EDGAR
  • Form C-UNov 23, 20220001665160-22-002968
    EDGAR
  • Form C/AOct 13, 20220001665160-22-002760
    EDGAR
  • Form C/ASep 21, 20220001665160-22-002458
    EDGAR
  • Form C/AAug 18, 20220001665160-22-002239
    EDGAR
  • Form C/AJun 16, 20220001665160-22-001820
    EDGAR
  • Form C/AJun 7, 20220001665160-22-001766
    EDGAR
  • Form C-ARApr 29, 20220001665160-22-001268
    EDGAR
Source: ManualCIK 0001916451DEShare price $1.39

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.